Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability

Backfill, Etl V1

ID: h-95fb48b4

Hypothesis

Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability

Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability starts from the claim that modulating C1QA, C3, C3AR1 (complement cascade) within the disease context of neuroinflammation can redirect a disease-rel.

🧬 C1QA, C3, C3AR1 (complement cascade)🩺 neuroinflammation🎯 Composite 42%💱 $0.50▲18.1%proposed

🧠 Neurodegeneration

EvidencePending (0%)📖 11 cit🗣 1 debates✓ 5 support✗ 6 oppose

✓ All Quality Gates Passed

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite42%

🧪 Overview

Mechanistic Overview

Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability starts from the claim that modulating C1QA, C3, C3AR1 (complement cascade) within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability starts from the claim that modulating C1QA, C3, C3AR1 (complement cascade) within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability starts from the claim that C1Q/C3 complement activation mediates the intersection of OxPC accumulation and synaptic loss. When microglia successfully neutralize OxPC via TREM2-APOE-ABCA1 axis, complement activation is suppressed and synapses are preserved. In aged microglia with impaired neutralization, OxPC drives C1Q secretion and C3 generation, opsonizing synapses for microglial phagocytosis via C3aR1.

...

Mechanistic Overview

Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability starts from the claim that modulating C1QA, C3, C3AR1 (complement cascade) within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability starts from the claim that modulating C1QA, C3, C3AR1 (complement cascade) within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability starts from the claim that C1Q/C3 complement activation mediates the intersection of OxPC accumulation and synaptic loss. When microglia successfully neutralize OxPC via TREM2-APOE-ABCA1 axis, complement activation is suppressed and synapses are preserved. In aged microglia with impaired neutralization, OxPC drives C1Q secretion and C3 generation, opsonizing synapses for microglial phagocytosis via C3aR1. Framed more explicitly, the hypothesis centers C1QA, C3, C3AR1 (complement cascade) within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. SciDEX scoring currently records confidence 0.55, novelty 0.58, feasibility 0.38, impact 0.40, mechanistic plausibility 0.62, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `C1QA, C3, C3AR1 (complement cascade)` and the pathway label is `Classical complement cascade`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Established background model links SASP to complement cascade amplification (C1Q/C3, confidence 0.70) providing a foundation mechanism that OxPC pathology would amplify. Identifier NA. 2. Source paper demonstrates microglial neutralization of OxPC prevents neuronal death suggesting failed neutralization produces diffusible signals (potentially complement) driving synaptic vulnerability. ^[1]. 3. TREM2, APOE, and ABCA1 regulate cholesterol storage (GO:0010885, FDR=8.9x10^-9) providing mechanistic link between lipid metabolism and complement regulation. Identifier NA (computational). 4. LGALS3 elevation would synergize with complement amplification through overlapping inflammatory pathways. ^[2]. 5. Hypothesis explains why aged microglia with impaired TREM2-SYK signaling and elevated LGALS3 show both failed OxPC neutralization and excessive synaptic pruning through shared complement-mediated mechanism. Identifier NA. ## Contradictory Evidence, Caveats, and Failure Modes 1. C3AR1 antagonist (avacopan) and other complement inhibitors have failed to meet primary endpoints in AD clinical trials with minimal efficacy. Identifier NA. 2. Complement inhibitors (eculizumab, ravulizumab) tested without meaningful cognitive benefit in AD. Identifier NA. 3. Causal direction is ambiguous - complement activation could be primary driver with OxPC accumulation as downstream consequence. Identifier NA. 4. C1Q is primarily astrocyte-derived in synaptic pruning contexts, not microglial - microglial contribution may be indirect. Identifier NA. 5. Synaptic loss in MS gray matter may not be complement-dependent - may be T-cell-mediated or excitotoxic. Identifier NA. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.3948`, debate count `1`, citations `11`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA, C3, C3AR1 (complement cascade) in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting C1QA, C3, C3AR1 (complement cascade) within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers C1QA, C3, C3AR1 (complement cascade) within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. SciDEX scoring currently records confidence 0.55, novelty 0.58, feasibility 0.38, impact 0.40, mechanistic plausibility 0.62, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `C1QA, C3, C3AR1 (complement cascade)` and the pathway label is `Classical complement cascade`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Established background model links SASP to complement cascade amplification (C1Q/C3, confidence 0.70) providing a foundation mechanism that OxPC pathology would amplify. Identifier NA. 2. Source paper demonstrates microglial neutralization of OxPC prevents neuronal death suggesting failed neutralization produces diffusible signals (potentially complement) driving synaptic vulnerability. ^[1]. 3. TREM2, APOE, and ABCA1 regulate cholesterol storage (GO:0010885, FDR=8.9x10^-9) providing mechanistic link between lipid metabolism and complement regulation. Identifier NA (computational). 4. LGALS3 elevation would synergize with complement amplification through overlapping inflammatory pathways. ^[2]. 5. Hypothesis explains why aged microglia with impaired TREM2-SYK signaling and elevated LGALS3 show both failed OxPC neutralization and excessive synaptic pruning through shared complement-mediated mechanism. Identifier NA. ## Contradictory Evidence, Caveats, and Failure Modes 1. C3AR1 antagonist (avacopan) and other complement inhibitors have failed to meet primary endpoints in AD clinical trials with minimal efficacy. Identifier NA. 2. Complement inhibitors (eculizumab, ravulizumab) tested without meaningful cognitive benefit in AD. Identifier NA. 3. Causal direction is ambiguous - complement activation could be primary driver with OxPC accumulation as downstream consequence. Identifier NA. 4. C1Q is primarily astrocyte-derived in synaptic pruning contexts, not microglial - microglial contribution may be indirect. Identifier NA. 5. Synaptic loss in MS gray matter may not be complement-dependent - may be T-cell-mediated or excitotoxic. Identifier NA. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.3948`, debate count `1`, citations `11`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA, C3, C3AR1 (complement cascade) in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting C1QA, C3, C3AR1 (complement cascade) within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers C1QA, C3, C3AR1 (complement cascade) within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`.

SciDEX scoring currently records confidence 0.55, novelty 0.58, feasibility 0.38, impact 0.40, mechanistic plausibility 0.62, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `C1QA, C3, C3AR1 (complement cascade)` and the pathway label is `Classical complement cascade`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Established background model links SASP to complement cascade amplification (C1Q/C3, confidence 0.70) providing a foundation mechanism that OxPC pathology would amplify. Identifier NA.

Source paper demonstrates microglial neutralization of OxPC prevents neuronal death suggesting failed neutralization produces diffusible signals (potentially complement) driving synaptic vulnerability. ^[1].

TREM2, APOE, and ABCA1 regulate cholesterol storage (GO:0010885, FDR=8.9x10^-9) providing mechanistic link between lipid metabolism and complement regulation. Identifier NA (computational).

LGALS3 elevation would synergize with complement amplification through overlapping inflammatory pathways. ^[2].

Hypothesis explains why aged microglia with impaired TREM2-SYK signaling and elevated LGALS3 show both failed OxPC neutralization and excessive synaptic pruning through shared complement-mediated mechanism. Identifier NA.

Contradictory Evidence, Caveats, and Failure Modes

C3AR1 antagonist (avacopan) and other complement inhibitors have failed to meet primary endpoints in AD clinical trials with minimal efficacy. Identifier NA.

Complement inhibitors (eculizumab, ravulizumab) tested without meaningful cognitive benefit in AD. Identifier NA.

Causal direction is ambiguous - complement activation could be primary driver with OxPC accumulation as downstream consequence. Identifier NA.

C1Q is primarily astrocyte-derived in synaptic pruning contexts, not microglial - microglial contribution may be indirect. Identifier NA.

Synaptic loss in MS gray matter may not be complement-dependent - may be T-cell-mediated or excitotoxic. Identifier NA.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.3948`, debate count `1`, citations `11`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA, C3, C3AR1 (complement cascade) in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting C1QA, C3, C3AR1 (complement cascade) within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Complement Activation"] --> B["C1q/C3b Opsonization"]
    B --> C["Synaptic Tagging"]
    C --> D["Microglial Phagocytosis"]
    D --> E["Synapse Loss"]
    F["C1QA Modulation"] --> G["Complement Cascade Block"]
    G --> H["Reduced Synaptic Tagging"]
    H --> I["Synapse Preservation"]
    I --> J["Cognitive Protection"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style J fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix5 supports6 contradicts

Supports

Established background model links SASP to complement cascade amplification (C1Q/C3, confidence 0.70) providing a foundation mechanism that OxPC pathology would amplify

PMID:NA

Supports

Source paper demonstrates microglial neutralization of OxPC prevents neuronal death suggesting failed neutralization produces diffusible signals (potentially complement) driving synaptic vulnerability

PMID:33603230

Supports

TREM2, APOE, and ABCA1 regulate cholesterol storage (GO:0010885, FDR=8.9x10^-9) providing mechanistic link between lipid metabolism and complement regulation

PMID:NA (computational)

Supports

LGALS3 elevation would synergize with complement amplification through overlapping inflammatory pathways

PMID:37208177

Supports

Hypothesis explains why aged microglia with impaired TREM2-SYK signaling and elevated LGALS3 show both failed OxPC neutralization and excessive synaptic pruning through shared complement-mediated mechanism

PMID:NA

Contradicts

C3AR1 antagonist (avacopan) and other complement inhibitors have failed to meet primary endpoints in AD clinical trials with minimal efficacy

PMID:NA

Contradicts

Complement inhibitors (eculizumab, ravulizumab) tested without meaningful cognitive benefit in AD

PMID:NA

Contradicts

Causal direction is ambiguous - complement activation could be primary driver with OxPC accumulation as downstream consequence

PMID:NA

Contradicts

C1Q is primarily astrocyte-derived in synaptic pruning contexts, not microglial - microglial contribution may be indirect

PMID:NA

Contradicts

Synaptic loss in MS gray matter may not be complement-dependent - may be T-cell-mediated or excitotoxic

PMID:NA

Contradicts

C1QA genetic variants are not strongly associated with AD risk in GWAS unlike TREM2 or APOE suggesting complement is not convergent mechanism

PMID:NA

📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — C1QA

🧬 PDB 1PK6 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for C1QA, C3, C3AR1 (complement cascade) from GTEx v10.

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for C1QA, C3, C3AR1 (complement cascade) →

No DepMap CRISPR Chronos data found for C1QA, C3, C3AR1 (complement cascade).

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

2.0 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↔

Stable

7d Momentum

▲ 0.3%

Volatility

Medium

0.0407

Events (7d)

2

Price History

▲18.1%

💾 Resource Usage

LLM Tokens

25,794

$0.0774

Total Cost

$0.0774

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
IF aged C57BL/6 mice are treated with a selective C3aR1 antagonist (e.g., SB 290157) for 4 weeks starting at 12 months of age, THEN hippocampal synaptic density (measured by PSD95/Shank3 western blot	Hippocampal PSD95 protein levels will increase by ≥30% and postsynaptic density puncta density will increase by ≥25% in C3aR1-antagonist-treated aged mice relat	— no observation —	pending	0.52
IF CSF C1Q/C3 ratio and plasma OxPC (16:0/18:1 oxidized species) are quantified in a stratified cohort of 200 subjects aged 60-85 with and without neuroinflammation biomarkers (TREM1 elevation, IL-1β	Subjects in the high OxPC/high C1Q/C3 stratum will demonstrate significantly elevated CSF NfL (≥150 pg/mL increase) and faster cognitive decline (≥1.5 points/ye	— no observation —	pending	0.48

🔮 Falsifiable Predictions (2)

pendingconf 52%

IF aged C57BL/6 mice are treated with a selective C3aR1 antagonist (e.g., SB 290157) for 4 weeks starting at 12 months of age, THEN hippocampal synaptic density (measured by PSD95/Shank3 western blot and confocal puncta analysis) will be significantly preserved compared to vehicle-treated aged contr

Predicted outcome: Hippocampal PSD95 protein levels will increase by ≥30% and postsynaptic density puncta density will increase by ≥25% in C3aR1-antagonist-treated aged

Falsification: No significant difference in synaptic density between C3aR1 antagonist and vehicle groups (p>0.05) OR synaptic preservation occurs without reduction in microglial C3aR1 activation markers (C3aR1/CD68

pendingconf 48%

IF CSF C1Q/C3 ratio and plasma OxPC (16:0/18:1 oxidized species) are quantified in a stratified cohort of 200 subjects aged 60-85 with and without neuroinflammation biomarkers (TREM1 elevation, IL-1β positivity), THEN subjects with high OxPC (>75th percentile) combined with high C1Q/C3 ratio (>75th

Predicted outcome: Subjects in the high OxPC/high C1Q/C3 stratum will demonstrate significantly elevated CSF NfL (≥150 pg/mL increase) and faster cognitive decline (≥1.5

Falsification: Subjects with high OxPC and high complement activation show equivalent synaptic vulnerability (CSF NfL, cognitive decline) to subjects with low complement markers despite high OxPC, indicating the pat

📖 References (2)

Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia.
Dong Y et al.. Nature neuroscience (2021)
PubMed↗DOI↗
Elevated Galectin-3 Is Associated with Aging, Multiple Sclerosis, and Oxidized Phosphatidylcholine-Induced Neurodegeneration.
The Journal of neuroscience : the official journal of the Society for Neuroscience (2023)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

0

Incoming

0

Outgoing

0

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

Composite		42%
Mech.		62%
Evidence		55%
Novelty		58%
Feasibility		38%
Impact		40%
Druggability		55%
Safety		35%
Competition		32%
Data avail.		60%
Reproducibility		58%

📗 Cite This Artifact

Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — C1QA

💉 Clinical Trials

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (2)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

📗 Cite This Artifact

Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — C1QA

💉 Clinical Trials

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

activates (4)

causal extracted (3)

causes (4)

co discussed (1)

modulates (2)

protective against (1)

regulates (2)

therapeutic target for (1)

🔮 Predictions

📖 References (2)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion